Description

The 2026 call by EUP OHAMR — titled “Treatments and adherence to treatment protocols” — aims to support international, multidisciplinary research and innovation projects that develop novel therapies, treatment strategies, or supportive interventions to combat antimicrobial resistance (AMR) in human, animal, and plant health contexts. The overarching goal is to improve treatment success rates of bacterial or fungal infections and to preserve and strengthen the efficacy of existing antimicrobials, thereby reducing AMR risk across the One Health spectrum.

Funding Amount

• Total call budget: Over €31 million.
• Per-project funding: no fixed per-project cap defined at the call level — funding is allocated by each participating national/regional funding organisation according to their own rules.
• Grant duration: Up to 3 years.

Submission Deadlines & Timeline

• Call opens: 18 November 2025
• Webinar for applicants: 26 November 2025
• Pre-proposal (first stage) deadline: 2 February 2026 (13:00 CET)
• Full-proposal (second stage) deadline: 17 June 2026 (13:00 CEST)
• Final funding recommendation announced: 30 October 2026
• Expected project start: between December 2026 and April 2027.

Submission Conditions & Eligibility Requirements

• The call supports transnational, collaborative research and innovation projects only. Individual or single-country applications are not eligible.
• Consortium composition requirements:
  • • Minimum of 3 eligible partners from 3 different eligible countries (of which at least two must be EU Member States or Horizon-associated countries).
    • Maximum of 6 project partners (including non-funded partners). Under certain conditions (e.g., inclusion of under-represented country, early-career researcher, SME/industry partner), consortia may include a 7th partner.
    • No more than two partners may receive funding from the same national funding organisation. For UK partners, this limit applies across both UK funding agencies.
    • A given Principal Investigator (PI) may coordinate only one pre-proposal / full proposal.
• Letters of Intent: At both pre-proposal and full-proposal stages, each partner (funded or non-funded) must submit a signed Letter of Intent. Without these, proposals are ineligible.
• Non-funded partners: Partners not requesting funding (for instance from non-eligible countries or outside national funding eligibility) can be included; their in-kind contribution must be declared and may not exceed 30% of the total requested project budget. Non-funded partners cannot be the consortium coordinator.
• Compliance with national/regional rules: Since funding is via national funders, partners must ensure they meet both the common call criteria and their national eligibility and regulatory requirements (on eligible costs, costing rules, allowed types of organisations, etc.).
• No overlap with other EU-funded AMR/Horizon calls: Proposals must not overlap with other ongoing or past projects funded under Horizon Europe, EU4Health or previous calls (e.g., projects under predecessor programmes such as JPIAMR). Overlap must be disclosed.

Eligible Types of Organisations

Consortia may include:

• Academic organisations (public and private universities, research institutes, higher-education institutions)
• Clinical / public-health institutions: hospitals, healthcare providers, public health organisations (including primary health care), and other health-care settings.
• Private companies of all sizes (start-ups, SMEs, larger industry) active in research and innovation — subject to eligibility under their national funding agency and applicable state-aid/regulation.
• Operational stakeholders: patient advocacy organisations, municipalities or local governments, NGOs — particularly those that can contribute context knowledge, stakeholder engagement, implementation capacity, or facilitate uptake of results.
• Non-funded partners from outside eligible countries may participate (with own funding), as long as they abide by consortium rules and contribute meaningfully to the project.

Eligible Countries

• 37 funding organisations from 28 different countries are participating in this call.
• Participating countries include: Austria, Belgium, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Slovakia, South Africa, Spain, Sweden, Switzerland, Türkiye, United Kingdom
• A valid consortium must include partners from at least three different eligible countries, with at least two being EU Member States or Horizon-associated countries.